See more : ASML Holding N.V. (ASML) Income Statement Analysis – Financial Results
Complete financial analysis of Athersys, Inc. (ATHX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athersys, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Transcend Information, Inc. (2451.TW) Income Statement Analysis – Financial Results
- Asian Energy Services Limited (ASIANENE.NS) Income Statement Analysis – Financial Results
- China Marine Information Electronics Company Limited (600764.SS) Income Statement Analysis – Financial Results
- TA-I Technology Co., Ltd. (2478.TW) Income Statement Analysis – Financial Results
- Gram Car Carriers ASA (G39.MU) Income Statement Analysis – Financial Results
Athersys, Inc. (ATHX)
About Athersys, Inc.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 5.51M | 1.43M | 5.52M | 23.74M | 2.84M | 16.24M | 10.30M | 286.00K | 755.00K | 7.38M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -554.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 5.51M | 1.43M | 5.52M | 24.29M | 2.84M | 16.24M | 11.95M | 1.62M | 2.44M | 8.71M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 102.33% | 100.00% | 100.00% | 116.02% | 567.48% | 322.91% | 117.99% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 65.03M | 71.08M | 62.99M | 39.05M | 38.66M | 27.84M | 24.84M | 21.32M | 23.37M | 20.48M | 19.64M | 18.93M | 14.78M | 11.92M | 16.50M | 15.82M | 0.00 | 12.58M | 0.00 | 13.68M |
| General & Administrative | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Other Expenses | 1.42M | 1.43M | 882.00K | 582.00K | 762.00K | 314.00K | 209.00K | -61.00K | 86.00K | 38.00K | -1.17M | 278.00K | 284.00K | 233.00K | 218.00K | 283.00K | 0.00 | 982.00K | 0.00 | 22.19M |
| Operating Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Cost & Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.00K | 85.00K | 203.00K | 375.00K | 1.15M | 1.59M | 0.00 | 317.00K | 0.00 | 644.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 243.00K | 0.00 | 0.00 | 94.00K | 1.26M | 0.00 | 964.00K | 0.00 | 135.00K |
| Depreciation & Amortization | 1.42M | 1.43M | 890.00K | 698.00K | 855.00K | 684.00K | 382.00K | 267.00K | 360.00K | 346.00K | 320.00K | 278.00K | 284.00K | 233.00K | 218.00K | 231.00K | 0.00 | 938.00K | 0.00 | 1.80M |
| EBITDA | -75.59M | -85.63M | -77.44M | -44.79M | -25.42M | -33.33M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -20.82M | -11.23M | -15.62M | -18.91M | -20.82M | -1.51K | -12.50M | 0.00 | -30.83M |
| EBITDA Ratio | -1,419.51% | -1,552.97% | -5,407.96% | -811.85% | -107.11% | -1,172.25% | -95.15% | -171.64% | -12,322.73% | -2,355.89% | -245.05% | -130.04% | -124.82% | -706.62% | -609.44% | -677.70% | 0.00% | -347.72% | 0.00% | -1,432.57% |
| Operating Income | -77.01M | -87.06M | -78.33M | -45.49M | -25.05M | -33.28M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -13.78M | -11.51M | -15.62M | -19.09M | -20.82M | -1.51K | -13.97M | 0.00 | -34.78M |
| Operating Income Ratio | -1,446.18% | -1,578.85% | -5,470.11% | -824.51% | -105.51% | -1,170.70% | -92.54% | -166.74% | -10,144.06% | -3,239.34% | -216.82% | -133.22% | -128.77% | -723.25% | -614.88% | -638.50% | 0.00% | -388.49% | 0.00% | -1,616.36% |
| Total Other Income/Expenses | 4.48M | 103.00K | -433.00K | 906.00K | 762.00K | 1.04M | -348.00K | 711.00K | 6.68M | -6.29M | 1.27M | 34.00K | 134.00K | 249.00K | 1.10M | -3.57M | -52.00K | -233.00K | 0.00 | -1.08M |
| Income Before Tax | -72.53M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.37M | -16.46M | -22.34M | -30.74M | -14.74M | -24.39M | -11.38M | -17.99M | -17.99M | -24.39M | 0.00 | -14.20M | 0.00 | -35.86M |
| Income Before Tax Ratio | -1,362.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.68% | -159.84% | -7,809.44% | -4,071.92% | -199.66% | -235.74% | -127.27% | -833.35% | -579.45% | -748.01% | 0.00% | -394.97% | 0.00% | -1,666.36% |
| Income Tax Expense | -4.47M | 0.00 | 0.00 | 0.00 | 762.00K | -728.00K | -37.00K | -38.00K | -253.00K | 6.32M | -2.44M | -34.00K | -134.00K | -249.00K | -1.10M | -1.84M | 1.51K | 924.00K | 0.00 | -547.00K |
| Net Income | -68.06M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.34M | -16.42M | -22.08M | -30.74M | -14.74M | -13.75M | -11.38M | -15.37M | -17.99M | -18.93M | -1.51K | -14.60M | 0.00 | -33.16M |
| Net Income Ratio | -1,278.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.45% | -159.47% | -7,720.98% | -4,071.92% | -199.66% | -132.89% | -127.27% | -711.72% | -579.45% | -580.55% | 0.00% | -405.98% | 0.00% | -1,540.94% |
| EPS | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -5.00 | -7.17 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| EPS Diluted | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -4.96 | -7.03 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| Weighted Avg Shares Out | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.29M | 3.08M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
| Weighted Avg Shares Out (Dil) | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.31M | 3.14M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further...
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update. Second Quarter 2023 and...
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of...
Athersys to Host Business Update Conference Call on August 9th
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo,...
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic Trauma
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients...
Athersys Restructures Debt with Supplier
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier (“the supplier”). The Company previously entered into agreements with the supplier to...
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update. First Quarter...
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care's (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma...
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants...
Source: https://incomestatements.info
Category: Stock Reports